Jean‐Charles Soria

89.8k total citations · 16 hit papers
679 papers, 34.8k citations indexed

About

Jean‐Charles Soria is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jean‐Charles Soria has authored 679 papers receiving a total of 34.8k indexed citations (citations by other indexed papers that have themselves been cited), including 416 papers in Oncology, 323 papers in Pulmonary and Respiratory Medicine and 223 papers in Molecular Biology. Recurrent topics in Jean‐Charles Soria's work include Lung Cancer Treatments and Mutations (251 papers), Cancer Genomics and Diagnostics (151 papers) and Cancer Immunotherapy and Biomarkers (98 papers). Jean‐Charles Soria is often cited by papers focused on Lung Cancer Treatments and Mutations (251 papers), Cancer Genomics and Diagnostics (151 papers) and Cancer Immunotherapy and Biomarkers (98 papers). Jean‐Charles Soria collaborates with scholars based in France, United States and Spain. Jean‐Charles Soria's co-authors include Fabrice André, Christophe Massard, Aurélien Marabelle, Sophie Postel‐Vinay, Benjamin Besse, Thierry Le Chevalier, Stéphane Champiat, Ken A. Olaussen, Charles Ferté and Élisabeth Brambilla and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Jean‐Charles Soria

667 papers receiving 34.3k citations

Hit Papers

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cis... 2006 2026 2012 2019 2006 2016 2018 2016 2018 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
    2006 1.3k citations Fabrice André, Jean‐Charles Soria et al. profile →
  2. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
    2016 867 citations Samy Ammari, Christophe Massard et al. Clinical Cancer Research profile →
  3. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
    2018 825 citations Samy Ammari, Antoine Hollebecque et al. profile →
  4. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
    2016 813 citations Émilie Routier, Jean‐Charles Soria et al. profile →
  5. T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
    2018 656 citations Patrick A. Ott, Yung‐Jue Bang et al. Journal of Clinical Oncology profile →
  6. Management of non-small-cell lung cancer: recent developments
    2013 592 citations Jean‐Charles Soria et al. profile →
  7. Dendritic cell–derived exosomes for cancer therapy
    2016 507 citations Fabrice André, Jean‐Charles Soria et al. profile →
  8. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
    2015 503 citations Émilie Routier, Jean‐Charles Soria et al. profile →
  9. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
    2018 451 citations Jean‐Charles Soria, Jean‐Marie Michot et al. profile →
  10. Optimizing oncolytic virotherapy in cancer treatment
    2019 384 citations Jean‐Charles Soria et al. profile →
  11. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
    2017 377 citations Patrick A. Ott, Yung‐Jue Bang et al. Journal of Clinical Oncology profile →
  12. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
    2015 324 citations Jean‐Charles Soria et al. profile →
  13. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
    2021 275 citations Jean‐Charles Soria et al. profile →
  14. Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
    2021 196 citations Fabrice André, Fabrice Barlési et al. Cancer Discovery profile →
  15. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
    2022 183 citations Jan H.M. Schellens, Jean‐Charles Soria et al. Annals of Oncology profile →
  16. Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
    2023 105 citations Jordi Remón, Benjamin Besse et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jean‐Charles Soria France 95 19.7k 13.0k 12.8k 6.8k 4.7k 679 34.8k
Richard Pazdur United States 106 19.8k 1.0× 10.6k 0.8× 10.3k 0.8× 5.2k 0.8× 3.7k 0.8× 596 37.7k
Ignacio I. Wistuba United States 99 16.4k 0.8× 16.8k 1.3× 12.4k 1.0× 9.0k 1.3× 4.2k 0.9× 687 36.0k
Ming‐Sound Tsao Canada 98 15.3k 0.8× 16.5k 1.3× 13.8k 1.1× 8.3k 1.2× 2.9k 0.6× 653 37.2k
Fabrice André France 95 20.5k 1.0× 13.9k 1.1× 13.0k 1.0× 14.1k 2.1× 4.8k 1.0× 675 38.0k
Howard A. Burris United States 89 25.4k 1.3× 13.0k 1.0× 10.7k 0.8× 6.2k 0.9× 3.3k 0.7× 741 38.2k
Hope S. Rugo United States 90 31.3k 1.6× 11.2k 0.9× 16.6k 1.3× 11.5k 1.7× 6.2k 1.3× 847 45.2k
Roy S. Herbst United States 102 31.9k 1.6× 17.0k 1.3× 26.5k 2.1× 9.2k 1.4× 5.5k 1.2× 583 50.9k
Guido Sauter Germany 93 13.6k 0.7× 17.6k 1.4× 10.0k 0.8× 8.1k 1.2× 2.7k 0.6× 600 35.0k
Charles Swanton United Kingdom 79 12.8k 0.6× 13.0k 1.0× 8.5k 0.7× 12.7k 1.9× 2.9k 0.6× 325 30.6k
José Baselga United States 98 25.8k 1.3× 19.7k 1.5× 14.1k 1.1× 9.8k 1.4× 2.6k 0.6× 484 46.7k

Countries citing papers authored by Jean‐Charles Soria

Since Specialization
Citations

This map shows the geographic impact of Jean‐Charles Soria's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Charles Soria with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Charles Soria more than expected).

Fields of papers citing papers by Jean‐Charles Soria

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Charles Soria. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Charles Soria. The network helps show where Jean‐Charles Soria may publish in the future.

Co-authorship network of co-authors of Jean‐Charles Soria

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Charles Soria. A scholar is included among the top collaborators of Jean‐Charles Soria based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Charles Soria. Jean‐Charles Soria is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dall’Olio, Filippo Gustavo, Damien Vasseur, Maryam Karimi, et al.. (2023). Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.. Journal of Clinical Oncology. 41(16_suppl). 2516–2516.
2.
Ribas, Antoni, Rajarshi Sengupta, Sayyed K. Zaidi, et al.. (2020). Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. Cancer Discovery. 11(2). 233–236. 132 indexed citations
3.
Kundu, Kiran, Susmita Ghosh, Rhitajit Sarkar, et al.. (2019). Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA. Cancer Immunology Research. 7(7). 1120–1134. 29 indexed citations
4.
Varga, Andréa, Jean‐Charles Soria, Antoine Hollebecque, et al.. (2019). A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 26(6). 1229–1236. 64 indexed citations
5.
Bahleda, Rastislav, Andréa Varga, Yann Bergé, et al.. (2018). Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. British Journal of Cancer. 118(3). 344–352. 7 indexed citations
6.
Pailler, Emma, Marianne Oulhen, Isabelle Borget, et al.. (2017). Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK -Rearranged Non–Small Cell Lung Cancer Patients. Cancer Research. 77(9). 2222–2230. 59 indexed citations
7.
Paik, Paul K., Ronglai Shen, Michael F. Berger, et al.. (2017). A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. Clinical Cancer Research. 23(18). 5366–5373. 115 indexed citations
8.
Ott, Patrick A., Yung‐Jue Bang, Dominique Berton-Rigaud, et al.. (2017). Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Journal of Clinical Oncology. 35(22). 2535–2541. 377 indexed citations breakdown →
9.
Aftimos, Philippe, Christian Rolfo, Sylvie Rottey, et al.. (2017). Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies. Clinical Cancer Research. 23(21). 6411–6420. 47 indexed citations
10.
Morel, Daphné, Geneviève Almouzni, Jean‐Charles Soria, & Sophie Postel‐Vinay. (2016). Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism. Annals of Oncology. 28(2). 254–269. 62 indexed citations
11.
Schwaederlé, Maria, Vladimir Lazar, Pierre Validire, et al.. (2015). VEGF-A Expression Correlates with TP53 Mutations in Non–Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy. Cancer Research. 75(7). 1187–1190. 96 indexed citations
12.
Zimmer, Lisa, Fabrice Barlési, Maria Martinez‐García, et al.. (2014). Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations. Clinical Cancer Research. 20(16). 4251–4261. 59 indexed citations
13.
Ferté, Charles, Andrew D. Trister, Erich Huang, et al.. (2013). Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology. Clinical Cancer Research. 19(16). 4315–4325. 33 indexed citations
14.
Guinney, Justin, Charles Ferté, Jonathan R. Dry, et al.. (2013). Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients. Clinical Cancer Research. 20(1). 265–272. 30 indexed citations
15.
Ferté, Charles, Yohann Loriot, Céline Clémenson, et al.. (2013). IGF-1R Targeting Increases the Antitumor Effects of DNA-Damaging Agents in SCLC Model: An Opportunity to Increase the Efficacy of Standard Therapy. Molecular Cancer Therapeutics. 12(7). 1213–1222. 42 indexed citations
16.
Ferté, Charles, Antoine Hollebecque, Serge Koscielny, et al.. (2013). Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials. Clinical Cancer Research. 20(1). 246–252. 130 indexed citations
17.
Martinez‐García, Maria, Udai Banerji, Joan Albanell, et al.. (2012). First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors. Clinical Cancer Research. 18(17). 4806–4819. 122 indexed citations
18.
Soria, Jean‐Charles, Jean‐Yves Blay, Jean-Philippe Spano, et al.. (2011). Added value of molecular targeted agents in oncology. Annals of Oncology. 22(8). 1703–1716. 36 indexed citations
19.
André, Fabrice, Mario Campone, Ruth O’Regan, et al.. (2010). Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab. Journal of Clinical Oncology. 28(34). 5110–5115. 148 indexed citations
20.
Besse, Benjamin, Stanislas Ropert, & Jean‐Charles Soria. (2007). Targeted therapies in lung cancer. Annals of Oncology. 18. ix135–ix142. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard Pazdur Breakdown of academic impact, for papers by Ignacio I. Wistuba Breakdown of academic impact, for papers by Ming‐Sound Tsao Breakdown of academic impact, for papers by Fabrice André Breakdown of academic impact, for papers by Howard A. Burris Breakdown of academic impact, for papers by Hope S. Rugo Breakdown of academic impact, for papers by Roy S. Herbst Breakdown of academic impact, for papers by Guido Sauter Breakdown of academic impact, for papers by Charles Swanton Breakdown of academic impact, for papers by José Baselga
Rankless by CCL
2026